14 results about "Hepatitis B virus core" patented technology

The invention discloses a virus-like structure nano adapter and application thereof, on the basis of hepatitis B virus core protein Uniprot P03146 of which nucleic acid binding domains at 145-183 sites of a C tail end are removed, CBP as shown in SEQ ID NO.01 is respectively inserted into a spike part and an N tail end of the hepatitis B virus core protein Uniprot P03146. The invention is constructed based on collagen combined polypeptide CBP designed by bionic decorrin, aims to imitate the interaction between natural decorrin and collagenous fiber, can efficiently cross over corneal epithelium barrier and repair corneal stroma in a non-photo-crosslinking manner, and solves the limitation of existing clinical treatment.

The invention belongs to the technical field of biological medicines, and particularly relates to an mRNA vaccine for preventing or treating hepatitis B virus infection and application of the mRNA vaccine. The mRNA vaccine comprises mRNA for coding hepatitis B virus surface antigen or / and hepatitis B virus core associated antigen or / and hepatitis B virus front surface antigen 1 fusion IgG Fc segment protein, and the mRNA is wrapped by lipid nanoparticles to form a delivery system to be prepared into the mRNA vaccine. The vaccine preparation can specifically enhance humoral immune response and cellular immune response aiming at hepatitis B virus surface antigen or / and hepatitis B virus core related antigen or / and hepatitis B virus front surface antigen, and can be used for preventing and treating hepatitis B. All the components in the vaccine preparation can be widely obtained, the vaccine cost is effectively reduced, the vaccine yield is increased, and therefore the vaccine preparation has good practical application value.

The present invention discloses a monoclonal antibody cAbB4 for hepatitis B virus core protein and its preparation and application. cAbB4 recognizes the core protein HBc of hepatitis B virus HBV. The amino acid sequences of CDR1-H, CDR2-H and CDR3-H of its heavy chain variable region are SEQ ID NO.1-3, respectively, and the amino acid sequences of CDR1-L, CDR2-L and CDR3-L of its light chain variable region are SEQ ID NO.4, "SGS" and SEQ ID NO.5, respectively. The monoclonal antibody obtained by screening of the present invention has a strong ability to bind to HBc. The present invention verifies the application of cAbB4 in various biochemical methods through examples, and verifies its ability to detect different HBV genotypes. The monoclonal antibody cAbB4 of the present invention has the characteristics of high efficiency, broad spectrum and versatility, and has broad application prospects in the field of HBV infection diagnosis.

The present invention discloses a monoclonal antibody cAbF9 against hepatitis B virus core protein and its preparation and application. cAbF9 recognizes the core protein HBc of hepatitis B virus HBV. The amino acid sequences of CDR1-H, CDR2-H, and CDR3-H in its heavy chain variable region are SEQ ID NO.1-3 respectively, and the amino acid sequences of CDR1-L, CDR2-L, and CDR3-L in its light chain variable region are SEQ ID NO.4, "SAS", and SEQ ID NO.5 respectively. The monoclonal antibody screened in the present invention has a strong binding ability to HBc. The present invention verifies the application of cAbF9 in various biochemical methods through examples, and verifies its ability to detect different HBV genotypes. The monoclonal antibody cAbF9 of the present invention has the characteristics of high efficiency, broad spectrum, and multi-purpose, and has broad application prospects in the field of HBV infection diagnosis.

The application discloses a recombinant virus-like nanoparticle for immunotherapy of gastric cancer and application thereof. The recombinant virus-like nanoparticle is a chimeric recombinant virus-like nanoparticle formed by self-assembly of a fusion protein HBC-CLDN18.2 of a hepatitis B virus core protein and CLDN18.2 tight junction protein. The application uses genetic engineering technology to truncate the C-terminal end of a natural hepatitis B virus core antigen, and mutate cysteine residues at positions 48 and 107 into serine, so that the hepatitis B virus core antigen can self-assemble into a virus-like nanoparticle with strong stability. The virus-like nanoparticle is used as a carrier, a B cell epitope peptide (tight junction protein CLDN18.2) of a gastric cancer tumor-related antigen is inserted into an immunodominant site of the carrier, so that the humoral immune response against gastric cancer is enhanced. Two T cell epitope peptides of the heterologous hepatitis B virus core antigen are used to replace T cell epitope peptides on the carrier, so that the cellular immune response against gastric cancer is enhanced, and strong antitumor effect and immune memory effect are shown.

The present invention discloses a monoclonal antibody against the core protein of hepatitis B virus and its preparation and application. The monoclonal antibody recognizes the core protein HBc of hepatitis B virus HBV. The monoclonal antibody is one of cAbB8, cAbD8, cAbE2, cAbE5, cAbE11, cAbF5, cAbF12, cAbH8 or any combination thereof. The monoclonal antibody obtained by screening in the present invention has a strong ability to bind to HBc. The present invention verifies the application of the monoclonal antibody in various biochemical methods through examples and verifies its ability to detect different HBV genotypes. The monoclonal antibody of the present invention has the characteristics of high efficiency, broad spectrum and versatility, and has broad application prospects in the field of diagnosis of HBV infection.

The present disclosure provides a photo-activated chemiluminescence detection kit and method for detecting hepatitis B virus core IgM type antibody. The detection kit comprises: reagent 1, luminescent microspheres coated with hepatitis B core antigen (HBcAg), which can react with singlet oxygen and generate a detectable light signal; reagent 2, anti-IgM antibody labeled with a first partner; and reagent 3, blocking reagent, which can reduce or eliminate interfering antibodies. The detection kit of the present disclosure destroys the structure of interfering antibodies by chemical and / or biological methods, thereby weakening or even eliminating the signal or shielded signal caused by interfering antibodies, which can significantly improve the accuracy of hepatitis B virus core IgM type antibody detection.

The present invention discloses a monoclonal antibody cAbA1 against the core protein of hepatitis B virus, and its preparation and application. cAbA1 recognizes the core protein HBc of hepatitis B virus HBV. The amino acid sequences of CDR1-H, CDR2-H, and CDR3-H of its heavy chain variable region are SEQ ID NO.1-3, respectively, and the amino acid sequences of CDR1-L, CDR2-L, and CDR3-L of its light chain variable region are SEQ ID NO.4, "GVS," and SEQ ID NO.5, respectively. The monoclonal antibody obtained by screening in the present invention has a strong ability to bind to HBc. The present invention verifies the application of cAbA1 in various biochemical methods through examples, and verifies its ability to detect different HBV genotypes. The monoclonal antibody cAbA1 of the present invention has the characteristics of high efficiency, broad spectrum, and versatility, and has broad application prospects in the field of HBV infection diagnosis.

The invention discloses a hepatitis B virus HBcrAg detection kit, which comprises an immunomagnetic bead working solution, a sample treatment solution and an HBcrAg labeling working solution, the immunomagnetic bead working solution comprises immunomagnetic beads coated with a coating antibody and a magnetic bead diluent; the sample treatment liquid is used for removing outer membranes of hepatitis B virus particles under mild conditions and dissociating hepatitis B virus core particles to release HBcrAg; the HBcrAg marking working solution comprises a marking antibody coupled with a marker and a marker diluent. The detection kit can effectively split the hepatitis B virus core particles under mild conditions, and can capture the hepatitis B virus core particles so as to avoid interference of endogenous antibodies, so that the content of HBcrAg in a sample is more accurately detected, the HBcAg index is measured, the traditional defect of two-in-half hepatitis B is made up, and the detection kit can be used for detecting the HBcrAg content of the sample and detecting the HBcrAg index. And iteration from'two pairs of hepatitis B 'to'three pairs of hepatitis B' is realized. The invention further discloses an HBcrAg detection method adopting the HBcrAg detection kit for the hepatitis B virus.

The present disclosure generally relates to novel crystalline forms of a certain compound which are useful as modulators of hepatitis B virus core protein assembly. The present disclosure also relates to identifying suitable solid forms with promising solid state properties for clinical development. The solid state forms disclosed may be used in the manufacture of drug products which may have allosteric effector properties against hepatitis B virus (HBV) core protein (Cp), a protein found as a dimer, a multimer, and as the protein shell of the HBV core. As one example, provided herein is a stable crystalline form which may be useful for treating viral infections, such as hepatitis B.

This invention provides a novel compound that can effectively prevent the proliferation of drug-resistant hepatitis B viruses. [Solution] A hydrophobic tag and morphothiazine, which is an allosteric modulator of the hepatitis B virus core protein, are linked by a linker. The ring-type carbocyclic is any of the following: adamantane ring, norbornene ring, norbornane ring, perhydroindene ring, decalin ring, perhydrofluorene ring, perhydroanthracene ring, perhydrophenanthrene ring, tricyclodecane ring, tricycloundecane ring, tetracyclododecane ring, perhydroacenaphthene ring, or perhydrophenalene ring. The novel compound according to the present invention can effectively suppress the proliferation of drug-resistant HBV.

The present disclosure generally relates to methods of synthesizing compounds useful as modulators of hepatitis B virus core protein assembly as well as novel synthetic intermediates. The methods disclosed may be used in the manufacture of compounds which may have allosteric effector properties against hepatitis B virus (HBV) core protein (Cp), a protein found as a dimer, a multimer, and as the protein shell of the HBV core. As one example, provided herein is a process for preparing compounds which may be useful for treating viral infections, such as hepatitis B.

The present invention relates to peptides and their ability to identify and bind to T cells specific for HBV-infected hepatocytes. In a first aspect of the invention, there is provided a peptide comprising an amino acid sequence selected from the group consisting of STLPETAVVRR (SEQ ID NO: 21), STLPETAVVR (SEQ ID NO: 22), STLPETTVVRR (SEQ ID NO: 23), STLPETTVTRR (SEQ ID NO: 24), STPPETTVVRR (SEQ ID NO: 25), STLPETTVVGR (SEQ ID NO: 26) and STIPETTVVRR (SEQ ID NO: 27), wherein the peptide is derived from Hepatitis B virus core169 and is capable of binding HLA-A*1101 and when bound to HLA-A*1101 is capable of identifying T cells specific for Hepatitis B virus. In a second aspect of the invention, there is provided a T cell expressing a T cell receptor (TCR) molecule, wherein the TCR molecule comprises an amino acid sequence selected from the group consisting of CASGDSNSPLHF (SEQ ID NO: 17), CASSGGQIVYEQYF (SEQ ID NO: 18), CSARGGRGGDYTF (SEQ ID NO: 19) and CASSQDWTEAFF (SEQ ID NO: 20), and wherein the TCR molecule is able to bind to a peptide according to the first aspect of the invention.

The present invention discloses a monoclonal antibody cAbD4 for hepatitis B virus core protein and its preparation and application. cAbD4 recognizes the core protein HBc of hepatitis B virus HBV. The amino acid sequences of CDR1-H, CDR2-H and CDR3-H of its heavy chain variable region are SEQ ID NO.1-3, respectively, and the amino acid sequences of CDR1-L, CDR2-L and CDR3-L of its light chain variable region are SEQ ID NO.4, "LGS" and SEQ ID NO.5, respectively. The monoclonal antibody obtained by screening of the present invention has a strong binding ability to HBc. The present invention verifies the application of cAbD4 in various biochemical methods through examples, and verifies its ability to detect different HBV genotypes. The monoclonal antibody cAbD4 of the present invention has the characteristics of high efficiency, broad spectrum and versatility, and has broad application prospects in the field of HBV infection diagnosis.